PBRM1 and nonpapillary renal cell carcinoma: Miao et al.6 demonstrated that in a series of nearly 100 metastatic clear cell renal cell carcinoma (ccRCC) patients, those harboring loss-of-function (LOF) mutations in PBRM1 had clinical benefit from ICB.